TrialFuture oncology (London, England)2024

Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.

Suresh S Ramalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.